Novartis engages patient representatives to learn more about their lived experience via a mechanism known as Patient Advisory Boards. Advisory Boards are established as and when they are needed and focus on exploring a specific topic or condition. Advisory Boards typically comprise of 8-10 patient representatives, either individuals or patient organisation representatives. Advisory Board members are identified from Novartis’ professional network of contacts, and they include recommendations received from patient organisations. The input received from Advisory Boards are achieved by Novartis and used to inform future strategy. From August-September 2019, Novartis supported more than 20 patient representatives to collect data about the lived experience of patients with serious heart conditions. In February and August 2020, Novartis Popit advisory board and Psoriasis advisory board hosted focus groups with 11 and 6 patient representatives, respectively.